Veloxis increases share capital in connection with exercise of warrants
Company Announcement no. 13/2016
To: NASDAQ OMX Copenhagen A/S Hørsholm, Denmark, 13 June 2016
Veloxis increases share capital in connection with exercise of warrants
Veloxis Pharmaceuticals A/S announces that the company's capital has been increased by 11,695,434 new shares with a nominal value of DKK 0.10 each corresponding to nominal DKK 1,169,543.40 as a consequence of the exercise of warrants by former employees of the company granted under the company's warrant program.
As a result of the employee's investment in the company proceeds to Veloxis Pharmaceuticals A/S from the capital increase amounts to DKK 4,141,239.
The subscription prices for the new shares are as follows (per share of nominal DKK 0.10):
6,911,734 shares DKK 0.35
4,783,700 shares DKK 0.36
The new shares will be listed on NASDAQ Copenhagen following registration of the capital increase with the Danish Business Authority, upon which the share capital of Veloxis Pharmaceuticals A/S will be DKK 169,907,388.10 divided into shares of DKK 0.10 each.
Each share of nominal DKK 0.10 carries one vote at general meetings in Veloxis Pharmaceuticals A/S. The new shares give rights to dividend and other rights from the time of registration of the capital increase with the Danish Business Authority.
For more information, please contact:
Craig A. Collard
President & CEO
Phone: +1 919 524 4317
Email: cac@veloxis.com
Veloxis Pharmaceuticals A/S (VELO)
Based in Hørsholm, Denmark, with an office in New Jersey, Veloxis Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company. Veloxis' unique, patented delivery technology, MeltDose®, is designed to enhance the absorption and bioavailability of select orally administered drugs. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.
For further information, please visit www.veloxis.com.
Vedhæftede filer:
130616 Veloxis Announces Exercise of Warrants.pdf